Akero Therapeutics Inc [AKRO] stock is trading at $45.85, up 4.63%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AKRO shares have gain 1.60% over the last week, with a monthly amount drifted -10.36%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on January 30, 2025, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $63 from $35. Previously, H.C. Wainwright reaffirmed its Buy rating on January 27, 2025, and elevated its price target to $72. On November 18, 2024, Citigroup initiated with a Buy rating and assigned a price target of $65 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $69 as its price target on September 19, 2023. UBS started tracking with a Buy rating for this stock on August 28, 2023, and assigned it a price target of $83. In a note dated January 27, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $40 to $65.
Akero Therapeutics Inc [AKRO] stock has fluctuated between $17.86 and $58.40 over the past year. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $45.85 at the most recent close of the market. An investor can expect a potential return of 9.05% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.32 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.72 points at the first support level, and at 43.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 47.05, and for the 2nd resistance point, it is at 48.24.
Ratios To Look Out For
For context, Akero Therapeutics Inc’s Current Ratio is 19.38. In addition, the Quick Ratio stands at 19.38 and the Cash Ratio stands at 8.56.
Transactions by insiders
Recent insider trading involved Cheng Andrew, President and CEO, that happened on Mar 10 ’25 when 30000.0 shares were sold. Chief Scientific Officer, Rolph Timothy completed a deal on Mar 05 ’25 to sell 12500.0 shares. Meanwhile, Chief Operating Officer Young Jonathan sold 50000.0 shares on Mar 04 ’25.
